MedTrace Logo

Radiofrequency Ablation Plus Radiotherapy for Small Hepatocellular Carcinoma

NCT03988998 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-01-18

No results posted yet for this study

Summary

Radiofrequency ablation (RFA) and hepatic resection are main treatments for early stage hepatocellular carcinoma. Many randomized controlled trials found these two treatments have similar short term overall survival. However, hepatic resection is associated with higher long-term overall survival. These results reveal that tumor recurrence rate after RFA is higher than that after hepatic resection. And minimal residual tumor may exist after RFA. Radiotherapy after RFA may be effective to prevent early tumor recurrence.

Conditions

Interventions

DRUG

Radiofrequency ablation with radiotherapy

Radiofrequency ablation with radiotherapy

DRUG

Radiofrequency ablation alone

Radiofrequency ablation without radiotherapy

Sponsors & Collaborators

  • Guangxi Medical University

    lead OTHER

Principal Investigators

  • Tang Wei-Zhong, PhD · Guangxi Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-10
Primary Completion
2022-12-31
Completion
2023-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03988998 on ClinicalTrials.gov